Preferred Label : bradykinin;
MeSH definition : A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood
where it is a potent but short-lived agent of arteriolar dilation and increased capillary
permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from
gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal,
and may be a neurotransmitter.;
MeSH synonym : arg pro pro gly phe ser pro phe arg; arg-pro-pro-gly-phe-ser-pro-phe-arg;
MeSH hyponym : bradykinin, (2-D-Pro)-Isomer; bradykinin, (7-D-Pro)-Isomer; bradykinin diacetate; bradykinin, (5-D-Phe)-Isomer; bradykinin, (2-D-Pro-7-D-Pro)-Isomer; bradykinin, (3-D-Pro-7-D-Pro)-Isomer; bradykinin, (9-D-Arg)-Isomer; bradykinin acetate, (9-D-Arg)-Isomer; bradykinin hydrochloride; bradykinin, (3-D-Pro)-Isomer; bradykinin, (8-D-Phe)-Isomer; bradykinin, (1-D-Arg)-Isomer; bradykinin, (6-D-Ser)-Isomer; bradykinin, (2-D-Pro-3-D-Pro-7-D-Pro)-Isomer; bradykinin, (5-D-Phe-8-D-Phe)-Isomer; bradykinin triacetate;
MeSH CAS label : bradykinin;
MeSH Related Number : bradykinin triacetate; bradykinin, (1-D-Arg)-Isomer; bradykinin, (2-D-Pro)-Isomer; bradykinin, (2-D-Pro-3-D-Pro-7-D-Pro)-Isomer; bradykinin, (2-D-Pro-7-D-Pro)-Isomer; bradykinin, (3-D-Pro)-Isomer; bradykinin, (3-D-Pro-7-D-Pro)-Isomer; bradykinin, (5-D-Phe)-Isomer; bradykinin, (5-D-Phe-8-D-Phe)-Isomer; bradykinin, (6-D-Ser)-Isomer; bradykinin, (7-D-Pro)-Isomer; bradykinin, (8-D-Phe)-Isomer; bradykinin, (9-D-Arg)-Isomer; bradykinin acetate, (9-D-Arg)-Isomer; bradykinin diacetate; bradykinin hydrochloride; 13865-66-2 ((6-D-Ser)-isomer); 14033-58-0 ((3-D-Pro)-isomer); 14109-47-8 (enantio, (2-L-Pro-3-L-Pro-7-L-Pro)-isomer); 14109-48-9 ((2-D-Pro-3-D-Pro-7-D-Pro)-isomer); 14109-50-3 ((2-D-Pro)-isomer); 15626-83-2 ((5-D-Phe)-isomer); 16511-76-5 ((8-D-Phe)-isomer); 18942-27-3 ((7-D-Pro)-isomer); 19187-64-5 (diacetate (salt)); 31021-87-1 ((5-D-Phe-8-D-Phe)-isomer); 487-75-2 ((1-D-Arg)-isomer); 487-77-4 ((9-D-Arg)-isomer); 53807-04-8 (HCl); 58-82-2 (Bradykinin); 5979-11-3 (triacetate (salt)); 634-56-0 (enantio); 6846-03-3 (acetate (salt)); 76094-83-2 ((3-D-Pro-7-D-Pro)-isomer); 76123-99-4 ((2-D-Pro-7-D-Pro)-isomer);
Registry Number MeSH : 58-82-2;
Related CAS MeSH : 19187-64-5 (Bradykinin diacetate); 53807-04-8 (Bradykinin hydrochloride); 5979-11-3 (Bradykinin triacetate); 487-75-2 (Bradykinin, (1-D-Arg)-Isomer); 14109-50-3 (Bradykinin, (2-D-Pro)-Isomer); 14109-48-9 (Bradykinin, (2-D-Pro-3-D-Pro-7-D-Pro)-Isomer); 76123-99-4 (Bradykinin, (2-D-Pro-7-D-Pro)-Isomer); 14033-58-0 (Bradykinin, (3-D-Pro)-Isomer); 76094-83-2 (Bradykinin, (3-D-Pro-7-D-Pro)-Isomer); 15626-83-2 (Bradykinin, (5-D-Phe)-Isomer); 31021-87-1 (Bradykinin, (5-D-Phe-8-D-Phe)-Isomer); 13865-66-2 (Bradykinin, (6-D-Ser)-Isomer); 18942-27-3 (Bradykinin, (7-D-Pro)-Isomer); 16511-76-5 (Bradykinin, (8-D-Phe)-Isomer); 487-77-4 (Bradykinin, (9-D-Arg)-Isomer); 6846-03-3 (Bradykinin acetate, (9-D-Arg)-Isomer);
Wikipedia link : https://en.wikipedia.org/wiki/Bradykinin;
Codes EINECS : 200-398-8;
Is substance : O;
UNII : S8TIM42R2W;
Origin ID : D001920;
UMLS CUI : C0006100;
Allowable qualifiers
- CISMeF manual mappings
- Currated CISMeF NLP mapping
- Indexing information
- B 10148 [MeSH Supplementary Concept]
- B 10206 [MeSH Supplementary Concept]
- B 10284 [MeSH Supplementary Concept]
- B 9340 [MeSH Supplementary Concept]
- BKM 870 [MeSH Supplementary Concept]
- BKM 872 [MeSH Supplementary Concept]
- Pharmacological action(s)
- Record concept(s)
- Related MeSH Supplementary Concept(s)
- B 10330 [MeSH Supplementary Concept]
- B 10380 [MeSH Supplementary Concept]
- B 3852 [MeSH Supplementary Concept]
- B 4146 [MeSH Supplementary Concept]
- B 4162 [MeSH Supplementary Concept]
- B 9340 [MeSH Supplementary Concept]
- B 9430 [MeSH Supplementary Concept]
- B 9858 [MeSH Supplementary Concept]
- B-9958 [MeSH Supplementary Concept]
- NPC 567 [MeSH Supplementary Concept]
- NPC 573 [MeSH Supplementary Concept]
- R 715 [MeSH Supplementary Concept]
- RMP 7 [MeSH Supplementary Concept]
- S 16118 [MeSH Supplementary Concept]
- T-kinin [MeSH Supplementary Concept]
- See also
- Semantic type(s)
- UMLS correspondences (same concept)
A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood
where it is a potent but short-lived agent of arteriolar dilation and increased capillary
permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from
gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal,
and may be a neurotransmitter.
https://www.has-sante.fr/portail/jcms/c_2873704/fr/firazyr
https://www.has-sante.fr/portail/jcms/c_2873704/fr/firazyr-icatibant
2018
false
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
icatibant acetate
icatibant
guidelines for drug use
hereditary angioedema types I and II
adult
icatibant
bradykinin
bradykinin
---
2018
false
France
French
child
adolescent
icatibant acetate
icatibant acetate
icatibant
orphan drug production
injections, subcutaneous
icatibant
bradykinin
hereditary angioedema types I and II
acute disease
emergency treatment
treatment outcome
icatibant
evaluation of the transparency committee
---
https://www.ansm.sante.fr/actualites/recommandations-dutilisation-des-inhibiteurs-de-la-c1-esterase-humaine-cinryze-et-berinert-en-periode-de-tensions-dapprovisionnement
2018
false
false
false
France
French
pharmacovigilance note
guidelines for drug use
SERPING1 protein, human
SERPING1 protein, human
injections, intravenous
infusions, intravenous
angioedemas, hereditary
angioedemas, hereditary
pregnancy
child
C1-inhibitor, plasma derived
SERPING1 protein, human
injections, subcutaneous
algorithms
icatibant
conestat alfa
recombinant proteins
conestat alfa
complement C1 inhibitor protein
complement C1 inhibitor protein
complement C1 inhibitor protein
icatibant
danazol
dexchlorpheniramine
histamine h1 antagonists
epinephrine
adult
complement c1 inactivator proteins
complement c1 inactivator proteins
complement c1 inactivator proteins
bradykinin
bradykinin
chlorpheniramine
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-01/firazyr__04012012_avis_ct11761.pdf
http://www.has-sante.fr/portail/jcms/c_1192693/firazyr
2012
France
French
icatibant
orphan drug production
injections, subcutaneous
icatibant
adult
bradykinin
hereditary angioedema types I and II
self administration
acute disease
emergency treatment
clinical trials, phase iii as topic
treatment outcome
icatibant
evaluation of the transparency committee
---
https://www.ema.europa.eu/medicines/human/EPAR/Firazyr
2012
false
United Kingdom
English
French
syndication feed
adolescent
child
bradykinin
bradykinin
drug approval
treatment outcome
drug labeling
adult
injections, subcutaneous
pregnancy
breast feeding
bradykinin
orphan drug production
receptor, bradykinin b2
drug evaluation, preclinical
icatibant
icatibant
hereditary angioedema types I and II
icatibant
package leaflet
drug evaluation
summary of product characteristics
---
https://www.revmed.ch/RMS/2011/RMS-278/Allergo-immunologie.-1.-Nouveautes-dans-le-traitement-des-crises-aigues-d-angioedeme-hereditaire
2011
false
true
false
Switzerland
bradykinin
angioedemas, hereditary
receptors, bradykinin
icatibant
journal article
angioedemas, hereditary
bradykinin
---
http://www.has-sante.fr/portail/jcms/c_724464/firazyr-ct-5904
http://www.has-sante.fr/portail/jcms/c_724460/firazyr
2008
France
French
orphan drug production
receptor, bradykinin b2
bradykinin
adrenergic beta-antagonists
adult
injections, subcutaneous
treatment outcome
pharmaceutical solutions
icatibant
hereditary angioedema types I and II
icatibant
rare diseases
evaluation of the transparency committee
---
